Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer

Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, and platelet-derived growth factor rece...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Onco Targets Ther
Autores principales: Lorusso, Loredana, Pieruzzi, Letizia, Biagini, Agnese, Sabini, Elena, Valerio, Laura, Giani, Carlotta, Passannanti, Paolo, Pontillo-Contillo, Benedetta, Battaglia, Valentina, Mazzeo, Salvatore, Molinaro, Eleonora, Elisei, Rossella
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5079697/
https://ncbi.nlm.nih.gov/pubmed/27799794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84625
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares